Huang Yadong, Su Zhijian, Li Yanmei, Zhang Qihao, Cui Lejia, Su Ye, Ding Changcai, Zhang Minjing, Feng Chengli, Tan Yi, Feng Wenke, Li Xiaokun, Cai Lu
Biopharmaceutical Research and Development Center, Institute of Life and Health Engineering, Jinan University, Guangzhou, Guangdong, China.
J Pharmacol Exp Ther. 2009 May;329(2):469-78. doi: 10.1124/jpet.108.149401. Epub 2009 Feb 10.
The present study aimed to produce and pathophysiologically evaluate the metallothionein (MT) fusion protein. A recombinant plasmid containing DNA segment coding the pET-glutathione transferase (GST)-small ubiquitin-related modifier (SUMO)-MT fusion protein was inserted into Escherichia coli for expression. The expression level of the fusion protein was very high, reaching to 38.4% of the total supernatant proteins from the organism. Subsequent filtration through glutathione Sepharose 4B gel and Sephadex G-25 yielded an MT fusion protein with purity more than 95%. When exposed to metals, E. coli containing the GST-SUMO-MT fusion protein showed an increased accumulation of Cd(2+), Zn(2+), or Cu(2+) at approximately 4.2, 4.0, or 1.6 times higher, respectively, than those containing the control protein. Administration of GST-SUMO-MT to mice that were also treated with D-galactose to induce neuronal and hepatic damage showed a significant improvement of animal learning and memory capacity, which was depressed in mice treated by D-galactose alone. Administration of MT fusion protein also prevented D-galactose-increased malondialdehyde contents and histopathological changes in the brain and liver. Furthermore, supplement of the fusion protein significantly prevented D-galactose-increased nitric oxide contents and -decreased superoxide dismutase activity in the brain, liver, and serum. The fusion protein was also able to prevent ionizing radiation-induced DNA damage of the mouse thymus. The present study indicates that GST-SUMO-MT has a normal metal binding feature and also significantly protects the multiple tissues against oxidative damage in vivo caused by chronic exposure to D-galactose and by ionizing radiation. Therefore, GST-SUMO-MT may be a potential candidate to be developed for the clinical application.
本研究旨在制备金属硫蛋白(MT)融合蛋白并对其进行病理生理学评估。将含有编码pET-谷胱甘肽S-转移酶(GST)-小泛素相关修饰物(SUMO)-MT融合蛋白DNA片段的重组质粒插入大肠杆菌进行表达。融合蛋白的表达水平非常高,达到生物体总上清蛋白的38.4%。随后通过谷胱甘肽琼脂糖4B凝胶和葡聚糖G-25过滤,得到纯度超过95%的MT融合蛋白。当暴露于金属时,含有GST-SUMO-MT融合蛋白的大肠杆菌对Cd(2+)、Zn(2+)或Cu(2+)的积累分别比含有对照蛋白的大肠杆菌增加约4.2、4.0或1.6倍。给同时用D-半乳糖处理以诱导神经和肝脏损伤的小鼠施用GST-SUMO-MT,显示动物学习和记忆能力有显著改善,而单独用D-半乳糖处理的小鼠的学习和记忆能力则受到抑制。施用MT融合蛋白还可防止D-半乳糖引起的大脑和肝脏中丙二醛含量增加和组织病理学变化。此外,补充融合蛋白可显著防止D-半乳糖引起的大脑、肝脏和血清中一氧化氮含量增加和超氧化物歧化酶活性降低。该融合蛋白还能够防止电离辐射诱导的小鼠胸腺DNA损伤。本研究表明,GST-SUMO-MT具有正常的金属结合特性,并且还能显著保护多个组织免受体内慢性暴露于D-半乳糖和电离辐射引起的氧化损伤。因此,GST-SUMO-MT可能是一种有潜力用于临床应用开发的候选物。